Published in Cell Death Dis on April 24, 2014
Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur J Clin Invest (2015) 1.08
Complement activation in the context of stem cells and tissue repair. World J Stem Cells (2015) 0.78
Interaction between Mesenchymal Stem Cells and B-Cells. Int J Mol Sci (2016) 0.78
Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood (2004) 13.79
Mesenchymal stem cells in health and disease. Nat Rev Immunol (2008) 11.14
Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol (2002) 6.92
Human mesenchymal stem cells modulate B-cell functions. Blood (2005) 5.12
Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica (2005) 3.11
Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol (2006) 3.00
Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy (2003) 2.28
Therapeutic potential of complement modulation. Nat Rev Drug Discov (2009) 1.85
Mycoplasma contamination of cell cultures: Incidence, sources, effects, detection, elimination, prevention. Cytotechnology (2002) 1.80
Adult mesenchymal stem cells: a pluripotent population with multiple applications. Curr Stem Cell Res Ther (2006) 1.51
Fatal septicemia due to Mycoplasma arginini: a new human zoonosis. Clin Infect Dis (1992) 1.51
Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol (2007) 1.46
Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. Curr Opin Immunol (2006) 1.44
Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells (2008) 1.42
Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch Pharm Res (2012) 1.37
Cell and gene therapy using mesenchymal stem cells (MSCs). J Autoimmun (2008) 1.30
Engrafted bone marrow-derived flk-(1+) mesenchymal stem cells regenerate skin tissue. Tissue Eng (2005) 1.29
The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol (2008) 1.29
Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood (2008) 1.26
Mesenchymal stem cells suppress B-cell terminal differentiation. Exp Hematol (2009) 1.25
The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica (2008) 1.24
Regulation of B lymphocyte activation by complement C3 and the B cell coreceptor complex. Curr Opin Immunol (2005) 1.22
Mycoplasmas and their host: emerging and re-emerging minimal pathogens. Trends Microbiol (2013) 1.20
Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. Nephrol Dial Transplant (2007) 1.17
Mesenchymal stem cells from human bone marrow or adipose tissue differently modulate mitogen-stimulated B-cell immunoglobulin production in vitro. Cell Biol Int (2008) 1.13
Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1. J Exp Med (2005) 1.04
Variations of clonal marrow stem cell lines established from human bone marrow in surface epitopes, differentiation potential, gene expression, and cytokine secretion. Stem Cells Dev (2008) 0.97
B-cell receptor cross-linking delays activation-induced cytidine deaminase induction and inhibits class-switch recombination to IgE. J Allergy Clin Immunol (2007) 0.95
CD21/CD35 in B cell activation. Semin Immunol (1998) 0.89
Complement receptor type 1 (CR1, CD35) is a potent inhibitor of B-cell functions in rheumatoid arthritis patients. Int Immunol (2012) 0.88
Compstatin inhibits complement activation by binding to the beta-chain of complement factor 3. Mol Immunol (2006) 0.88
Mesenchymal stem cells support proliferation and terminal differentiation of B cells. Cell Physiol Biochem (2012) 0.85
Mycoplasma contamination revisited: mesenchymal stromal cells harboring Mycoplasma hyorhinis potently inhibit lymphocyte proliferation in vitro. PLoS One (2011) 0.84
Umbilical cord mesenchymal stem cells suppress B-cell proliferation and differentiation. Cell Immunol (2012) 0.83
Eosinophilic Fasciitis associated with Mycoplasma arginini infection. J Clin Microbiol (2011) 0.80
Mice expressing human CR1/CD35 have an enhanced humoral immune response to T-dependent antigens but fail to correct the effect of premature human CR2 expression. Immunobiology (2011) 0.80
[Lipid-associated membrane lipopeptides of M. arginini activate NF-kB by interacting with TLR2/1, TLR2/6, and TLR2/CD14]. Mol Gen Mikrobiol Virusol (2009) 0.77
Bloodstream infection due to Mycoplasma arginini in an immunocompromised patient. J Clin Microbiol (2012) 0.76